SNES vs NEOG vs IDXX vs RGEN

For growth investors, SenesTech, Inc.

(SNES) is the stronger pick with 19. 6% revenue growth year-over-year, versus -3. 2% for Neogen Corporation (NEOG). IDEXX Laboratories, Inc. (IDXX) offers the better valuation at 43. 7x trailing P/E (38. 3x forward), making it the more compelling value choice. Analysts rate IDEXX Laboratories, Inc. (IDXX) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, IDEXX Laboratories, Inc.

(IDXX) is the cheapest at 43. 7x versus Repligen Corporation at 147. 0x. On forward P/E, Neogen Corporation is actually cheaper at 25. 3x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, IDEXX Laboratories, Inc.

(IDXX) delivered a total return of +5. 1%, compared to -99. 9% for SenesTech, Inc. (SNES). Over 10 years, the gap is even starker: IDXX returned +542. 3% versus SNES's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), IDEXX Laboratories, Inc.

(IDXX) is the lower-risk stock at 1. 36β versus Repligen Corporation's 1. 71β — meaning RGEN is approximately 25% more volatile than IDXX relative to the S&P 500. On balance sheet safety, SenesTech, Inc. (SNES) carries a lower debt/equity ratio of 28% versus 67% for IDEXX Laboratories, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), SenesTech, Inc.

(SNES) is pulling ahead at 19. 6% versus -3. 2% for Neogen Corporation (NEOG). On earnings-per-share growth, the picture is similar: Repligen Corporation grew EPS 287. 0% year-over-year, compared to -114. 6% for Neogen Corporation. Over a 3-year CAGR, SNES leads at 29. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

IDEXX Laboratories, Inc.

(IDXX) is the more profitable company, earning 24. 6% net margin versus -287. 4% for SenesTech, Inc. — meaning it keeps 24. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IDXX leads at 31. 6% versus -292. 9% for SNES. At the gross margin level — before operating expenses — SNES leads at 62. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Neogen Corporation (NEOG) trades at 25.

3x forward P/E versus 61. 7x for Repligen Corporation — 36. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IDXX: 30. 6% to $747. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, IDEXX Laboratories, Inc.

(IDXX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+542. 3% 10Y return). Neogen Corporation (NEOG) carries a higher beta of 1. 69 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IDXX: +542. 3%, NEOG: -50. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SNES (Basic Materials) and NEOG (Healthcare) and IDXX (Healthcare) and RGEN (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SNES is a small-cap high-growth stock; NEOG is a small-cap quality compounder stock; IDXX is a mid-cap quality compounder stock; RGEN is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.